Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789750 · ClinicalTrials.gov registry record · Phase 3
Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 562
- Enrollment target
NCT00789750: Completed Phase 3 study, sponsored by Daiichi Sankyo.
NCT00789750 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 562 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00789750, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 562 participants
- Enrollment target
Study Summary
The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in combination with either metformin or a sulfonylurea. The study will evaluate if colesevelam add-on to pioglitazone therapy for type 2 diabetes mellitus will be safe, well tolerated, and efficacious.
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG Colesevelam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 562 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
What the finished NCT00789750 record still lists
NCT00789750 is an interventional study that assigns participants to a tested intervention. The registered 562 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00789750 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00789750 about?
NCT00789750 is a clinical study titled "Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus". The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in combination with either metformin or a sulfonylurea. The study will evaluate i...
What is the current status of trial NCT00789750?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 562 participants. The study started on 2009-04. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00789750?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), Colesevelam (DRUG).
Who is sponsoring clinical trial NCT00789750?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00789750's enrollment target sits among peer trials
562 669th of 2000 higher than 1,331 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07007065 · 561 participants · Phase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia